Balyasny Asset Management
TXMD icon

Balyasny Asset Management’s TherapeuticsMD TXMD Stock Holding History

Balyasny Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-432
Closed -$56K – 1605
2019
Q2 		$56K Buy
+432
New +$77.4K ﹤0.01% 1423
2019
Q1 		– Sell
-232
Closed -$44K – 1669
2018
Q4 		$44K Sell
232
-502
-68% -$122K ﹤0.01% 1338
2018
Q3 		$241K Sell
734
-201
-21% -$61.6K ﹤0.01% 1554
2018
Q2 		$292K Buy
935
+652
+230% +$199K ﹤0.01% 1529
2018
Q1 		$69K Buy
283
+45
+19% +$12.6K ﹤0.01% 1851
2017
Q4 		$72K Buy
+238
New +$66.3K ﹤0.01% 1998
2017
Q3 		– Sell
-8,237
Closed -$2.17M – 2101
2017
Q2 		$2.17M Sell
8,237
-18,380
-69% -$4.6M 0.01% 923
2017
Q1 		$9.58M Buy
26,617
+3,097
+13% +$958K 0.04% 508
2016
Q4 		$6.79M Buy
23,520
+7,489
+47% +$2.32M 0.04% 604
2016
Q3 		$5.46M Buy
+16,031
New +$5.85M 0.03% 485
2016
Q2 		– Sell
-252
Closed -$81K – 1460
2016
Q1 		$81K Buy
+252
New +$86K ﹤0.01% 1213
2015
Q4 		– Sell
-4,950
Closed -$1.45M – 1456
2015
Q3 		$1.45M Buy
+4,950
New +$1.76M 0.01% 698

Other funds holding TXMD

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's TXMD Position: Q3 2019 in Review

Balyasny Asset Management sold out of TherapeuticsMD (TXMD) in Q3 2019, closing a stake of 432 shares — an estimated $56K sold.

Balyasny Asset Management first reported a position in TXMD in Q3 2015 and held it in 12 quarters. The position peaked at $9.58M in Q1 2017. 150 funds tracked by Wall St. Rank hold TXMD as of Q3 2019.

  • Balyasny Asset Management reported no remaining TherapeuticsMD position as of Q3 2019 after selling out during the quarter.
  • Balyasny Asset Management sold 432 TherapeuticsMD shares in Q3 2019, an estimated $56K.
  • Balyasny Asset Management first reported a position in TherapeuticsMD in Q3 2015 and held it in 12 quarters.
  • Balyasny Asset Management's TherapeuticsMD position peaked at $9.58M in Q1 2017.
  • 150 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2019.

Based on Balyasny Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.